Medication which decreases stomach acid
POPULARITY
8 episodes with zantac
6 episodes with zantac
3 episodes with zantac
10 episodes with zantac
6 episodes with zantac
2 episodes with zantac
3 episodes with zantac
2 episodes with zantac
3 episodes with zantac
Story at-a-glance Pepcid (famotidine) uniquely blocks serotonin activity unlike other H2 blockers, helping interrupt chronic pain, inflammation and fatigue caused by elevated serotonin levels A 70-year-old patient's life-threatening serotonin syndrome was rapidly reversed within 15 minutes using intravenous famotidine, demonstrating its powerful anti-serotonin effects Elevated serotonin impairs mitochondrial energy production and drives chronic inflammation, depression and pain, contrary to the popular "feel-good chemical" misconception Pepcid is safer than recalled Zantac (ranitidine) and more potent than older H2 blockers, with fewer drug interactions and decades of proven safety Unlike proton pump inhibitors (PPIs) with serious long-term risks, Pepcid offers a safer approach by targeting serotonin overload while providing effective heartburn relief
The tricky business of boosting vitamin D; New doubts over prospect of extending lifespan to 150; Reduced sitting time found to curb back pain; GSK settles Zantac lawsuits for $2.2 billion; Incorrect arm position may lead to false elevation in blood pressure readings.
Happy Halloween! It is time for a special themed episode of the Cut to the Chase: Podcast! The theme? Mass tort “horror stories”. Depo-Provera is the latest bone-chilling mass tort case that's scaring people left and right. Depo-Provera is a birth control injection linked to an increased risk of cranial meningiomas, or brain tumors. However, this new mass tort litigation looks promising due to the clear causation, single defendant (Pfizer), and prescription documentation. In this frightening episode, Count Dracula [our host Gregg Goldfarb] takes over as host to welcome Amy Barrie, a Mass Tort Acquisition Strategist at Broughton Partners and Host of the Purpose Driven Law Podcast. Amy helps law firms strategically diversify their case portfolios and navigate the intricate landscape of mass torts. She's been involved in mass tort litigation for over seven years and has worked on some of the most compelling cases, like Zantac and Camp Lejeune. Tune in to hear Amy's expert breakdown of the Depo-Provera mass tort, how it compares to previous cases, and strategic advice on safely entering the mass tort market. As Amy and “Dracula” both hint, the journey to justice might be spooky, but with the right knowledge, it's far from terrifying. Remember to make wise choices under the eerie moonlight of mass tort litigation… Good night and beware the torts lurking in the dark! What to expect in this episode: Details of the Depo-Provera mass tort case The significance of causation rates in mass torts Lessons learned from previous cases like Zantac The importance of diversifying strategies in mass tort litigation How to collaborate with reputable firms for better case handling Ethical considerations and protecting your practice Hauntingly humorous insights from Dracula himself! Key Actionable Takeaways for Law Firms & Parents: Diversify Your Portfolio: Always have a mix of cases to spread risk and opportunities. Align with Reputable Firms: Partner with firms that have the requisite infrastructure and trial experience. Educate Yourself: Stay updated on the intricacies and required documentation for mass tort cases. Strategize Early: Early involvement in litigation can lead to significant roles and better case quality. Ethical Practice: Ensure ethical advertising and client handling to protect your reputation and bar card. Stay tuned for more updates, and don't miss our next deep dive on Cut to The Chase: Podcast with Gregg Goldfarb! Subscribe, rate, review, and share this episode of the Cut to the Chase: Podcast to stay ahead in your legal practice! Resources: Connect with Amy Barrie on LinkedIn: https://www.linkedin.com/in/amybarrie Follow Amy on Instagram: https://www.instagram.com/itsabarrie Follow Broughton Partners on Instagram: https://www.instagram.com/broughtonpartners Learn more about Broughton Partners: https://www.broughtonpartners.com This episode was produced and brought to you by Reignite Media.
On this week's episode of Biotech Hangout, hosts Chris Garabedian, Bruce Booth, Josh Schimmer, Eric Schmidt and Sam Fazeli start the show on the topic of M&A and ponder “where are the deals?” as they consider potential reasons such as the U.S. election, too few assets or too few buyers. The conversation turns to the venture funding environment with a preview of the third quarter venture funding numbers. On the theme of stock price reactions, the group digs into why Sarepta's has dropped despite its gene therapy now fully approved and discusses Soleno's stock jump on the news from regulators to not hold an advisory meeting over its new drug application. In other news, the group highlights another China deal, this time between AstraZeneca and CSPS Pharma for a pre-clinical novel lipid-lowering therapy. The hosts also discuss the move by Lily to go after the compounding pharmacies, GSK agrees to settle Zantac lawsuits and the latest on Pfizer and Starboard which leads to a broader discussion on activism in biopharma. Regarding data, the hosts cover GSK's RSV data, Scholar Rock's spinal muscular atrophy data, among other topics. *This episode aired on October 11, 2024.
GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code Josh to save money! GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! Josh Sigurdson reports on the massive increase in cancers including so-called "Turbo Cancer" following the rollout of the "Covid vaccines" as cancer cases in England are set to hit a record high with almost 1,000 people diagnosed a DAY! The WHO expects a 77% increase on top of that in cancer cases by 2050, though by the way things are moving, it'll be far worse than that. While doctors scratch their heads for some reason, other scientists and doctors point out the obvious culprits. The Covid "vaccines," the fluoride in the water, the glyphosate in the foods, the spraying of the skies, the prescription drug industry and many other correlations. Moderna has admitted themselves in their patent that their "Covid vaccines" cause cancer. Pfizer was forced to admit that cancer causing SV40 is in their injections. Childhood vaccines have also been shown unequivocally to be a major cause of cancer in children and adults alike over time. Colon cancer and throat cancer is through the roof in children tragically. Vaccines are to blame, but so are GMOs as people are spoon-fed dangerous glyphosate in the food supply. 100 million Americans are said to live in areas with massive amounts of forever chemicals which cause cancer in their water supply. That's not even counting what the National Cancer Institute itself once called one of the number one causes of cancer on Earth... Fluoride or hydrofluosilicic acid. 7,100 bottles of anti-depressants were just recalled due to causing cancer. Pharma giant GSK was just caught knowingly giving people anti-heartburn medication "Zantac" despite a massive cancer risk. It took a whistleblower saying something. Johnson & Johnson was previously caught covering up the same in baby powder. Wireless technology continues to be a major risk to cancer and DNA. Most just laugh it off but countless studies prove this danger to be real as the establishment creates a dangerous hive mind based on nano-technology and frequency. Cancer causing chemicals have also been found recently in meat packaging. The examples go on and on. There are potentially very real yet censored solutions out there like apricot seeds (laetrile, amygdalin, vitamin b17) which we've covered many times and helped to debunk the big pharma myths around it. There's also things like CBD-A. Most refuse to acknowledge potential natural solutions. We're not saying it's a cure but look at the testimonies and decide for yourself whether you want to have a line of defense or try a different treatment. It could save you or with the worst-case scenario, it doesn't affect you. That's not a bad worst-case. We must start taking this seriously because we're being targeted daily. Stay tuned for more from WAM! GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/ USE Code WAM to save 5%! GET FREEZE DRIED BEEF HERE: https://wambeef.com/ Use Code WAMBEEF to save 25%! 10+ Year Shelf life & All Natural! GET TICKETS TO ANARCHAPULCO HERE: https://anarchapulco.com/ Save money by using code WAM GET YOUR FREEDOM KELLY KETTLE KIT HERE: https://patriotprepared.com/shop/freedom-kettle/ Use Code WAM and enjoy many solutions for the outdoors in the face of the impending reset! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-wam-cover-history/ PayPal: ancientwonderstelevision@gmail.com FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! Pledge here! Just a dollar a month can help us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2024
The tricky business of boosting vitamin D; New doubts over prospect of extending lifespan to 150; Reduced sitting time found to curb back pain; GSK settles Zantac lawsuits for $2.2 billion; Incorrect arm position may lead to false elevation in blood pressure readings.
The UK's Conservatives line up their two finalists to lead the party, Japan's Prime Minister Shigeru Ishiba dissolves parliament ahead of the Oct. 27 snap election, Donald Trump takes the lead for the White House in Florida, Tim Walz calls for abolishing the Electoral College, Volodymyr Zelenskyy reveals the first phase of Ukraine's “Victory Plan", Hurricane Milton makes landfall in Florida, global wildlife populations see a 73% decline in just 50 years, Indian business icon Ratan Tata passes away at the age of 86, the UK's GSK agrees to settle 80K US lawsuits over its heartburn drug Zantac, and Rafael Nadal retires from tennis. Sources: https://www.verity.news/
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.GSK has settled Zantac lawsuits for $2.2 billion, resolving 93% of product liability cases regarding allegations that the heartburn drug could cause cancer. Analysts are now shifting focus to the company's vaccines business. In other news, pediatric patients treated with Bluebird Bio's gene therapy developed blood cancers, Pfizer's phase III prostate cancer trial results may lead to a broader label for Talzenna-Xtandi combo, and Gritstone Bio has filed for bankruptcy in an effort to save its clinical research in cancer and infectious disease.On the marketing front, Hershey is using AI to refine its media strategy for the high-stakes Halloween season, with executives emphasizing the importance of targeting and timing, especially with the holiday falling just before the U.S. elections. United Airlines has successfully brought its Kinective media network to market, with the managing director of strategic partnerships sharing lessons learned and discussing future plans. However, a report from Interbrand indicates that a focus on performance marketing has cost brands trillions due to a lack of investment in long-term strategy. PepsiCo Foods' creative chief discussed in-housing and borderless content strategies, while Mountain Dew refreshed its visual identity to align with a new era of marketing. Duracell's CMO shared lessons on bringing low-interest brands into culture, and Diageo highlighted how AI helps them target audiences and navigate regulatory waters.Stay tuned for more updates on upcoming events, company announcements, and resources on customer engagement, retail trends, and more in the marketing industry.
From the BBC World Service: Ratan Tata was one of India’s most internationally recognized industrialists. The tycoon oversaw a 50-fold rise in profits in his two decades as chairman of Tata Group and acquired brands like carmaker Jaguar Land Rover. He died at age 86. Also: How is Swedish furniture giant Ikea going to hit its eco targets? Plus, the drugmaker behind Zantac agrees to a huge payout.
From the BBC World Service: Ratan Tata was one of India’s most internationally recognized industrialists. The tycoon oversaw a 50-fold rise in profits in his two decades as chairman of Tata Group and acquired brands like carmaker Jaguar Land Rover. He died at age 86. Also: How is Swedish furniture giant Ikea going to hit its eco targets? Plus, the drugmaker behind Zantac agrees to a huge payout.
This Day in Legal History: Outer Space Treaty Enters Into ForceOn October 10, 1967, the Outer Space Treaty, formally known as the "Treaty on Principles Governing the Activities of States in the Exploration and Use of Outer Space, including the Moon and Other Celestial Bodies," entered into force. This landmark agreement established a framework for the peaceful use and exploration of outer space, making it a key pillar of international space law. It was signed by the United States, the Soviet Union, and the United Kingdom, and has since been ratified by over 100 nations.The treaty explicitly prohibits the placement of nuclear weapons or other weapons of mass destruction in orbit, on the Moon, or on any other celestial body. It also bans military activities and the establishment of military bases in space. One of its central tenets is that space is to be used for the benefit of all humankind, with no country allowed to claim sovereignty over outer space or any celestial body.This treaty was negotiated during the height of the Cold War, reflecting both superpowers' mutual interest in preventing the militarization of space. By laying the groundwork for cooperation and peaceful exploration, it paved the way for future international agreements on space activities, including those addressing environmental concerns and the use of space resources. The Outer Space Treaty remains a cornerstone of space law today, as space exploration continues to evolve and expand.The Fifth Circuit Court of Appeals overturned a $47 million copyright infringement award against Grande Communications Networks LLC, an internet service provider (ISP), on Wednesday. Music publishers, including UMG Recordings and Warner Bros. Records, initially won the award after Grande was found liable for contributing to users' piracy of over 1,400 songs. However, the appeals court ruled that damages should not be awarded for each individual song, but rather for each album, sending the case back to the Texas district court for a new trial on damages. The court affirmed that Grande had failed to prevent repeated piracy by not terminating infringing subscribers, but found that the lower court had erred in its interpretation of statutory damages. This decision aligns with other rulings, such as one involving ISP Cox Communications, where liability for music piracy was affirmed, but damages were reconsidered.Appeals Court Undoes $47 Million Music Piracy Award Against ISPGSK has agreed to settle around 80,000 lawsuits, paying up to $2.2 billion over claims that the discontinued heartburn drug Zantac caused cancer. This settlement covers about 93% of the cases pending in U.S. state courts. The drugmaker maintains that there is no consistent evidence linking Zantac's active ingredient, ranitidine, to cancer but decided to settle to avoid prolonged litigation. Additionally, GSK will pay $70 million to settle a related whistleblower case. Zantac, once a blockbuster drug, faced scrutiny after the FDA in 2020 found that ranitidine could break down into a carcinogen, NDMA. Other pharmaceutical companies like Pfizer and Sanofi have also reached settlements, but Boehringer Ingelheim continues to face trials. In a recent Delaware ruling, plaintiffs were allowed to present expert testimony linking Zantac to cancer, while a Florida federal court had dismissed around 50,000 cases due to unreliable evidence. GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln | ReutersFTX investors have voluntarily dropped their class action lawsuit against Sullivan & Cromwell, a prominent U.S. law firm. The investors had accused the firm of aiding FTX's multibillion-dollar fraud and benefiting as FTX's lead bankruptcy counsel. However, lead attorney Adam Moskowitz stated that after reviewing reports by FTX bankruptcy examiner Robert Cleary, there was no valid claim against the law firm. Cleary's reports found no evidence that Sullivan & Cromwell was complicit in FTX's collapse or that it ignored warning signs while representing former FTX CEO Sam Bankman-Fried. Sullivan & Cromwell welcomed the withdrawal of what it called "meritless claims." The lawsuit had alleged that the firm had unique insight into FTX's lack of internal controls and questionable practices. Meanwhile, FTX's bankruptcy plan, approved this week, will allow the company to repay customers using $16.5 billion in recovered assets. Plaintiffs' attorneys also reached a separate agreement with the FTX bankruptcy estate regarding customer claims. FTX investors drop lawsuit against law firm Sullivan & Cromwell | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe
Got a Dilemma? https://www.thenewblxck.com/dilemma Interested In Securing Shares In THE NEW BLXCK -https://app.seedlegals.com/en/pitch/c_VoSPUCwhTo/The-New-Blxck Any questions about this investment opportunity, please contact Brent@TheNewBlxck.com The Day After, (00:00) Intro: House keeping (13:25) BHM: Lest We Forget (22:44) Headlines: Starmer fails to rule out increases to employer National Insurance contributions, Tory leadership race enters final stretch after shock result in ballot of MPs, Biden and Netanyahu speak as Gallant warns of ‘deadly' surprise attack on Iran (28:01) What You Saying? Everything is as it's always been...the only difference is perspective (01:04:41) Headlines: New enforcement agency will protect workers' rights as part of ‘watershed' bill, Investigation into surgeon widened to include four more London hospitals, Trump gaining in polling to win the ‘Blue Wall' states as Harris poll momentum slows (01:08:12) Word on Road The Carter's lawyer gave Piers Morgan an ultimatum Dr Dre being sued for $10M by his ex marriage counsellor TW:// Ex-boyfriend of Diddy accuser alleges she's lying TW:// Yung Filly arrested in Australia over alleged r*pe (02:24:23) The People's Journal: Major overhaul of workers' rights to be outlined, Spain looks to immigrants to drive economy, Tesla to unveil Cybercab, UK firm GSK to pay $2.2bn over Zantac cancer claims (02:33:05) Asking For A Friend: (02:43:53) Headlines: Turkish Airlines pilot dies mid-flight forcing crew to make an emergency landing in NYC, Four of Elon Musk's top execs call it quits at Tesla, Controversy surrounds Ghana's unpassed anti-LGBTQ law (02:46:41) The Reaction: UEFA Nations League Fixtures, Harry Kane out & John Stones to captain England in Nations League clash, Former Sheffield United defender George Baldock dies at 31, Former Premier League striker Nile Ranger desires to make positive impact with young players (02:52:13) Done Out Ere: (02:57:44) Wrap Up: #News #currentaffairs #sports
Llega la hora de la verdad para el primer ministro Michel Barnier que presenta esta tarde en el Consejo de Ministros un presupuesto con el que pretende ahorrar 60.000 millones de euros y subidas de impuestos para 2025. "Será un presupuesto difícil, serio y responsable", repite Barnier. El objetivo, reducir el déficit público al 5% en 2025 y luego al 3% en 2029, de acuerdo con las exigencias de Bruselas. Mientras, en el Reino Unido el primer ministro Keir Starmer impulsa la mayor reforma laboral en el país en una generación. Cuando la ley entre en vigor, a partir de 2026, millones de trabajadores podrán cobrar durante su baja por enfermedad desde el primer día y no desde el cuarto, como sucede ahora. En clave empresarial, la británica GSK pagará cerca de 2.200 millones de dólares para resolver un macro juicio en EEUU que reúne cerca de 80.000 casos de contaminación en uno de sus medicamentos, Zantac. Y Deutsche Telekom presenta en su "Capital Markets Day" la estrategia del grupo para iniciar una nueva fase de crecimiento. Hablaremos con José Luis García-Ochoa, de la correduría de seguros García-Ochoa. Y los temas de la actualidad los debatiremos en la tertulia de Cierre de Mercados con Pedro Fernández, abogado y profesor, e Isabel Giménez, de la Fundación de Estudios Bursátiles y Financieros.
Estamos pendientes esta hora de la reacción de los distintos activos al dato más esperado de la semana. También al de empleo semanal. Se mira con atención la subida de los rendimientos en deuda. Los del bund alemán están en máximos de cinco semanas. Durante la mañana, las ganancias en los sectores de salud y telecomunicaciones compensaban las pérdidas de los valores tecnológicos. Entre los valores individuales, GSK gana cerca de un 6% después de que la farmacéutica británica acordara pagar hasta 2.200 millones de dólares para resolver las demandas presentadas en EEUU en las que se alegaba que su medicamento para la acidez Zantac, ya descatalogado, causaba cáncer. BMW baja un 0,7% después de que haya presentado una caída en las ventas del tercer trimestre, perjudicada por el débil rendimiento en China y las paradas en las entregas. El análisis esta hora es de Diego Puertas, de Serenity Markets.
London's FTSE 100 eased higher ahead of a big day on the US tech front with Nvidia and CrowdStrike to report later. London's blue-chip index was up five points at 8,349 in early trades. GSK was a riser as the Delaware Supreme Court said it would review a previous adverse ruling in its Zantac litigation battle. The UK pharma company noted that such interlocutory reviews are granted in ‘exceptional circumstances'. Sports Direct owner Frasers has purchased a 14.65% strategic investment in Accent, a leading retail and distribution business in the performance and lifestyle market in Australia and New Zealand. Prudential fell after a mixed set of interims that were affected by the economic woes in Hong Kong and China. Even so, the life insurer maintained its forecast for new business growth of 15-20% over the next three years. Finally, the water sector has said that a proposed cap on bill hikes will create a risk of failures across the industry. An average £19 a year ceiling “would likely result in significant investability issues for the sector as a whole,” said the report from trade body WaterUK. #proactiveinvestors #ftse #footsie #ftse100 #marketreport #nvidia #crowdstrike #frasers #sportsdirect #gsk #zantac #prudential #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
This Day in Legal History: WWI Spy ConvictedOn August 16, 1918, Lothar Witzke became the first German spy convicted by the United States during World War I. Tried by a military commission at Fort Sam Houston, Texas, Witzke was found guilty of espionage for his role in sabotage activities against the U.S., including his alleged involvement in the Black Tom explosion, a major act of sabotage in 1916. His conviction marked a significant moment in the U.S.'s efforts to counter German espionage during the war. Witzke was sentenced to hang, but his fate took a turn when President Woodrow Wilson commuted his sentence on May 27, 1920. The commutation reflected the complexities of wartime justice and international relations. Later, in 1922, President Calvin Coolidge granted Witzke a pardon, leading to his deportation to Berlin. Witzke's case highlighted the U.S. government's determination to crack down on espionage while also navigating the diplomatic and political nuances of post-war justice.India's legal market is cautiously opening to foreign law firms under new guidance allowing them to practice international law within the country. However, only a few firms have taken steps to establish a presence, as many remain hesitant due to past challenges and uncertainties about the implementation of these new rules. India's rapid economic growth and favorable business environment under Prime Minister Narendra Modi make it an attractive prospect for foreign firms, but the memory of previous failed attempts and local opposition leads many to adopt a wait-and-see approach.Some firms are opting for strategies like the "fly in, fly out" model, running operations from nearby locations like Singapore. Others, like Baker McKenzie and Dentons, are planning to establish offices when permitted, but are currently working through collaborations with local firms. Japan-based TNY Legal and GVA Professional have already entered the Indian market to support their clients' growing needs.Despite the opportunities, significant hurdles remain, including unclear regulations and potential resistance from the local bar. Implementing legislation is still required, and foreign firms face a complex bureaucracy. The possibility of limits on foreign registrations to protect Indian firms adds to the uncertainty, making the path forward for foreign law firms in India fraught with challenges. India Sees Foreign Law Firms Take Baby Steps to Set Up OutpostsTikTok is challenging a U.S. law requiring its parent company, China-based ByteDance, to sell its U.S. assets or face a ban, arguing that the U.S. Department of Justice has misrepresented the app's ties to China. TikTok maintains that its data and content moderation decisions for U.S. users are handled within the U.S. and that the law infringes on its free speech rights. The law, signed by President Biden, aims to end Chinese ownership of TikTok due to national security concerns. The case will be heard by a federal appeals court in September, just before the November presidential election.TikTok disputes US claims on China ties in court appeal | ReutersThe Ninth Circuit Court of Appeals upheld California's vote-by-mail system, ruling that it does not violate the constitutional rights of in-person voters, even if some invalid mailed ballots are occasionally counted. The court rejected the claim that counting these ballots dilutes the votes of in-person voters, emphasizing that such errors do not disproportionately affect any particular group. The decision arose from a lawsuit aiming to decertify California's 2020 election results, which, if successful, could have favored Donald Trump. The court found that the plaintiffs' "vote dilution" theory was legally unfounded, consistent with rulings from other circuits.California Vote-By-Mail Upheld in Rebuke of ‘Vote Dilution' SuitGSK plans to seek the dismissal of a Zantac-related lawsuit in Florida, where plaintiffs allege the heartburn drug caused prostate cancer. This follows a recent Florida court ruling in GSK's favor, which excluded expert testimony linking ranitidine, Zantac's active ingredient, to prostate cancer. The ruling aligns with a 2022 federal court decision that dismissed similar cancer-related claims. However, a Delaware court ruling in June allowed over 70,000 lawsuits to proceed, permitting expert testimony that Zantac causes cancer. GSK is appealing the Delaware decision, as the majority of Zantac cases are concentrated there. Concerns over ranitidine's potential to degrade into the carcinogen NDMA led to the FDA pulling Zantac from the market five years ago.GSK to seek dismissal of Florida case against heartburn drug Zantac | ReutersBayer achieved a legal victory as a U.S. appeals court ruled that federal law shields the company from liability in a lawsuit claiming its Roundup weed killer causes cancer. The 3rd U.S. Circuit Court of Appeals in Philadelphia decided that federal regulations, which require uniform pesticide labeling, preempted Pennsylvania state law from mandating a cancer warning on Roundup. This ruling came in response to a lawsuit by David Schaffner, a landscaper diagnosed with non-Hodgkin's lymphoma, who argued that Bayer's Monsanto unit failed to warn consumers about the cancer risk. The decision could lead to a U.S. Supreme Court review due to conflicting rulings from other federal appeals courts, potentially impacting Bayer's broader litigation risk. Bayer, which has settled much of the Roundup litigation for $10.9 billion but still faces tens of thousands of claims, welcomed the ruling, asserting that Roundup and its active ingredient glyphosate are safe.Bayer wins victory in US legal battle against Roundup cancer claims | ReutersThis week's closing theme is by Franz Schubert.This week's closing theme brings us to the world of Franz Schubert, a composer whose music bridges the Classical and Romantic eras with remarkable emotional depth and lyrical beauty. Schubert, born in Vienna in 1797, was a prolific composer despite his tragically short life, leaving behind a vast body of work that continues to resonate with audiences today. Among his numerous compositions, his Piano Quintet in A major, D. 667, known as the "Trout Quintet," and his symphonies are often celebrated, but today we focus on one of his masterpieces in chamber music: his Piano Quintet in F minor, Op. 15.The first movement, "Allegro con fuoco ma non troppo," showcases Schubert's unique ability to blend intensity with elegance. The title, which translates to "fast, with fire but not too much," perfectly encapsulates the movement's spirit. It opens with a passionate and fiery theme that immediately captures the listener's attention, setting the stage for a dynamic interplay between the piano and strings. As the movement progresses, Schubert masterfully balances this intensity with moments of lyrical beauty, creating a musical narrative that is both dramatic and profoundly moving.This piece exemplifies Schubert's gift for melody and his deep understanding of the human experience, qualities that have endeared his music to generations of listeners. As you listen to the "Allegro con fuoco ma non troppo," let yourself be carried by its sweeping phrases and the emotional journey it offers—a true testament to Schubert's genius.Without further ado, the first movement of Franz Schubert's Fantasie in C major, Op. 15, popularly known as the Wanderer Fantasy. Enjoy. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe
This Day in Legal History: NASA CreatedOn July 29, 1958, President Dwight D. Eisenhower signed the National Aeronautics and Space Act, officially establishing the National Aeronautics and Space Administration (NASA). This landmark legislation was a response to the Soviet Union's launch of Sputnik in 1957, which marked the beginning of the space race. The act represented a significant shift in U.S. priorities, emphasizing the importance of space exploration for national security, scientific advancement, and international prestige. NASA was charged with the responsibility of conducting civilian space research and development, distinguishing it from military operations in space.The creation of NASA consolidated several existing organizations, including the National Advisory Committee for Aeronautics (NACA), into a single entity focused on space exploration. This integration aimed to foster innovation and streamline efforts in advancing aerospace technology. NASA's establishment marked the start of an era of unprecedented achievements, including the Apollo moon landings, the development of the Space Shuttle, and numerous scientific missions to explore our solar system and beyond.The act also emphasized the peaceful exploration of space, setting a tone for international cooperation. NASA's formation underscored the United States' commitment to leading the world in space exploration and scientific discovery. This pivotal moment in legal and scientific history laid the groundwork for decades of exploration, research, and technological advancements that have had profound impacts on society and our understanding of the universe.President Joe Biden plans to propose significant reforms to the U.S. Supreme Court, including term limits for justices and a binding code of conduct. Announced during a speech at former President Lyndon B. Johnson's library, these reforms also include a constitutional amendment to remove broad presidential immunity. Biden's proposals follow a series of Supreme Court rulings that countered his policies and come shortly after he ended his reelection bid, endorsing Vice President Kamala Harris against Donald Trump.Biden emphasized the principle that no one is above the law, including the president and Supreme Court justices. His reforms would require justices to disclose gifts, avoid political activities, and recuse themselves from cases with conflicts of interest. The proposals come after the Court adopted a non-binding code of conduct in response to undisclosed travel by Justice Clarence Thomas and other controversies.However, the reality is passing these reforms through a divided Congress is unlikely. The proposed constitutional amendment to limit presidential immunity would be particularly challenging, requiring broad legislative support and state ratifications.Joe Biden: My plan to reform the Supreme Court and ensure no president is above the law - The Washington PostBiden Calls for Strict New Limits on US Supreme Court JusticesBiden to propose Supreme Court term limits, binding code of conduct | ReutersThe U.S. Department of Justice has urged a federal appeals court to uphold a law mandating that China-based ByteDance sell TikTok's U.S. assets by January 19 or face a ban. The DOJ asserts that TikTok's Chinese ownership poses a significant national security risk, citing potential data access and covert content manipulation by the Chinese government. Despite TikTok's denials of sharing user data with China, the DOJ emphasized the threat's seriousness. The Biden administration seeks to dismiss lawsuits from TikTok, ByteDance, and TikTok creators opposing the law.The government highlighted extensive national security concerns, even though it admitted no evidence that China had accessed U.S. user data. TikTok criticized the government for not providing proof and acting on secret information. A classified document with further security concerns has also been submitted. ByteDance's source code, comprising 2 billion lines, is deemed too extensive for a thorough review.The law, signed by President Biden, aims to end Chinese ownership of TikTok on national security grounds without banning the app outright. The DOJ dismissed TikTok's First Amendment claims, noting other social media alternatives. TikTok's proposed $2 billion data protection plan was considered insufficient by the DOJ. The legal challenge's oral arguments are set for September 16, just weeks before the presidential election.Justice Dept. asks court to reject TikTok challenge to crackdown law | ReutersBritish drugmaker GSK has confidentially settled a lawsuit in Illinois claiming its discontinued heartburn drug Zantac caused cancer. Zantac, first approved in 1983 and once the world's best-selling medicine, faced scrutiny after the FDA requested its market withdrawal in 2020. The FDA's concerns centered on ranitidine, Zantac's active ingredient, potentially degrading into a carcinogen. GSK, along with Pfizer, Sanofi, and Boehringer Ingelheim, faces over 70,000 lawsuits in Delaware and numerous other claims.Despite the settlement, GSK did not admit liability and plans to defend itself in remaining cases. Following the settlement news, GSK's shares rose by 0.8%.GSK settles another heartburn drug lawsuit in Illinois | ReutersMaryland has enacted the Gift Card Scams Prevention Act of 2024, the nation's first law to protect against gift card fraud, specifically card draining. Card draining involves criminals stealing gift cards from stores, capturing their numeric codes, and then replacing them for unsuspecting customers to purchase. When loaded with money, these cards allow thieves to steal the balance online. This new law mandates secure packaging for most gift cards sold in stores to prevent tampering.The legislation faced significant industry opposition, with retailers and gift card manufacturers lobbying against it. Despite this, the law requires both open-loop (e.g., Visa, Mastercard) and closed-loop (e.g., Target, Applebee's) cards to have secure packaging that shows signs of tampering. The bill's passage marks a significant step in addressing the surge in gift card fraud that escalated during the pandemic.Maryland's law is expected to have a national impact, as companies typically prefer to use uniform packaging across all states. This could lead to widespread adoption of more secure packaging practices. The law goes into effect next June, giving companies a year to comply. The hope is that this measure will significantly reduce the incidence of gift card fraud, benefiting consumers nationwide.The Nation's First Law Protecting Against Gift Card Draining Has Passed. Will It Work? This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe
Digital Self.., FDA Juul ban is off… Zantac causes cancer lawsuit moves on... Poppi and gut health claims… Sajaks last night at the wheel… New Hunger Games book coming /Movie already in the works… Dolly Parton story on Broadway… Netflix sued by “inspiration” for Baby Reindeer?... www.chewingthefat@theblaze.com NBA Finals… NHL starts Sat... What movies are out? Alamo Draft House Locks the doors… www.blazetv.com/jeffy Promo code Jeffy… Game Show: What's The Lie?Contestant: Wesley Castelhano… Learn more about your ad choices. Visit megaphone.fm/adchoices
S&P Futures are displaying some positive indications this morning. It's a big week for the market with employment data and an ECB meeting scheduled for this week. Friday's Non-Farm Payrolls report will likely be the key economic data point of the week. Over the weekend NVDA & AMD presented a roadmap on chip development, which is helping to keep AI enthusiasm high. GSK is down hard this morning as courts believe that there is a link between its Zantac drug and cancer. In Europe, markets are higher on the back of this morning PMI releases and ahead of the ECB announcement on monetary policy this week. Oil prices are mixed to lower; Sunday's OPEC meeting was neutral to slightly bearish for oil prices.
This is a free preview of a paid episode. To hear more, visit www.minimumcomp.comAdministrative Update: We have an important update for Minimum Competence. Moving forward, our newsletter will be available exclusively to paid members, while the podcast will remain free for everyone. This change will allow us to dedicate more time and resources to enhancing the quality and content of Minimum Competence. We believe this is the best route forward to ensure we continue providing valuable insights and updates. We sincerely thank everyone for their understanding and continued support.This Day in Legal History: First Federal Child Labor Law Deemed UnconstitutionalOn June 3, 1918, the United States Supreme Court ruled in Hammer v. Dagenhart that the Keating-Owen Child Labor Act was unconstitutional. This landmark decision marked a significant moment in the legal battle over child labor laws in the United States. The Keating-Owen Act, passed in 1916, aimed to regulate child labor by prohibiting the interstate shipment of goods produced by children under certain ages and conditions. However, the Supreme Court, in a 5-4 decision, found that the Act exceeded the powers granted to Congress under the Commerce Clause of the Constitution.
London's FTSE 100 ticked higher on Monday, with the prospect of a blockbuster IPO also adding to the good feeling in the City. Chinese fast-fashion giant Shein is reportedly close to filing for its London listing in the coming weeks and is expected to receive a valuation of around £52 billion. However, before the listing is approved it is likely to come under scrutiny from both political parties due to allegations of Shein's unethical operations. GSK tumbled after a ruling from a court judge in Delaware allowed more than 70,000 Zantac lawsuits to go forward. Under the new ruling, expert witnesses will now be able to testify in court and argue that the heartburn drug may cause cancer. GSK said it disagrees with the judge's decision and plans to appeal it, arguing that the expert witnesses' opinion lacks scientific support. Finally, Hipgnosis, the embattled music royalty fund, has agreed with Blackstone over a takeover worth US$1.58 billion, or US$1.31 per share. #proactiveinvestors #marketreport #ftse #ftse100 #footsie #gsk #shein #hipgnosis #blackstone #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
Las Bolsas europeas se mantienen en verde esperando la apertura de los mercados americanos. Ya abrieron al alza siguiendo las ganancias de las asiáticas. Mientras, los inversores se preparan para una decisión clave sobre los tipos de interés del Banco Central Europeo esta semana. El índice paneuropeo STOXX 600 sube un 0,5%, ampliando sus ganancias por tercera sesión consecutiva. La actividad industrial de China creció en mayo al ritmo más rápido en dos años, mientras que el dato de inflación de Estados Unidos, más moderado el viernes, siguió alentando las esperanzas de que la Reserva Federal recorte los tipos de interés este año. Todas las miradas se centrarán ahora en la decisión sobre los tipos de interés del BCE del jueves, donde se espera que el banco central recorte sus tasas en 25 puntos básicos desde sus niveles récord. La mayoría de los índices sectoriales cotizan al alza, con los valores tecnológicos entre los que más suben, cerca de un 1%. Entre los valores individuales, la farmacéutica británica GSK se desploma un 10% después de que un juez de Estados Unidos admitiera a trámite más de 70.000 demandas por el medicamento Zantac, contra la acidez estomacal. En Bolsa española, y dentro del Ibex, Acciona Energías Reonovables, Solaria y Grifols protagonizan los mayores avances. Las pérdidas son para Unicaja, Ferrovial y BBVA, entre otros. Esta hora tenemos análisis con Diego Puertas, de Serenity Markets.
Welcome to The Daily Wrap Up, a concise show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (5/10/24). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble"); Rumble("play", {"video":"v4rxlct","div":"rumble_v4rxlct"}); Video Source Links (In Chronological Order): Medical Coder Blows The Whistle On The COVID-19 Illusion Pfizer agrees to settle 10,000 lawsuits accusing pharma giant of hiding cancer risks of heartburn drug Zantac (30) Taylor Hudak on X: "Do not fall for this new, scripted re-writing of history regarding C19 jabs In Feb 2021, several drs & scientists wrote to EMA warning about the risks of blood clots, strokes, autoimmune disease & more in an effort to stop the harm! The EMA did nothing! https://t.co/C3Vi0jbkxG https://t.co/PpxU7g9YL6" / X (30) Tommy Mac on X: "I'm shocked, shocked I tell you! "Elon Musk's Neuralink chip malfunctions in first in-human brain implant" https://t.co/WRGmyqm0Vt via @nypost" / X Elon Musk's Neuralink chip suffers unexpected setback in first in-human brain implant Bethany Christian Services (32) The Last American Vagabond on X: "In the last week TLAV has been blocked from streaming on @instagram & unceremoniously deleted from @tiktok_us with zero explanation. This while we are being told it is ALLOWING negative content about Israel.. I guess until you prove it with source material, as usual. Nothing new. https://t.co/DHvn6U0MyH" / X New Tab (30) The Last American Vagabond on X: ""I have never seen a similar case of hundreds of bees attacking one person," Well they do say bees can smell fear
Deficiently Mass-Produced - Profit Driven Quality StandardsWebsite: http://www.battle4freedom.com/studio/?pursuit-of-godlessnessNetwork: https://www.mojo50.comStreaming: https://www.rumble.com/Battle4Freedomhttps://www.biblegateway.com/passage/?search=Prov.29.12&version=CJBProverbs 29:12If a ruler listens to lies, all his officials will be wicked.https://www.dailymail.co.uk/news/article-13395857/Gang-rape-horror-14-year-old-girl-organised-boyfriend-DOZEN-children-aged-just-TWELVE-16-arrested-shocking-incident-saw-Belgian-victim-lured-ambush.htmlGang-rape horror of 14-year-old girl - 'organised by her boyfriend': TEN children aged between just ELEVEN and 16 are arrested over shocking incident that saw Belgian victim 'lured into ambush'https://www.dailymail.co.uk/news/article-13329985/Woman-died-trying-cure-cancer-juice-diet.htmlWoman who tried to cure her cancer with holistic diet drink almost died after she refused chemotherapy - with ex-model, 39, now saying 'you'll need something harder than carrot juice' to overcome tumoursIrena Stoynova sough alternatives to chemotherapy online when diagnosedhttps://www.dailymail.co.uk/health/article-13380109/us-states-botched-surgeries-misdiagnosis.htmlMap shows the states where doctors are most likely to bungle your surgeryOver last decade, 513,270 malpractice reports were made to a national databaseLouisiana had the highest average rate of reports, while Hawaii had the lowesthttps://www.dailymail.co.uk/health/article-13395481/ultra-processed-foods-30-year-study-risk-early-death.htmlFresh health warning over ultra-processed foods as 30-year study warns they marginally raise your risk of an early death - but not ALL types of UPFs will send you to an early grave, experts warnHarvard University researchers tracked 115,000 Americans over three decades https://www.dailymail.co.uk/health/article-13395913/New-documents-credibly-Covid-DID-leak-Wuhan-lab-China-covered-say-House-Republicans.htmlNew documents 'credibly show' Covid DID leak from Wuhan lab and China covered it up, say House Republicanshttps://www.dailymail.co.uk/health/article-13379597/neurosurgeon-brain-damaged-paralyzed-covid-vaccines-anti-vaxxers.htmlNeuroscientist, 37, and nurse, 54, claim they were left brain damaged and paralyzed from Covid vaccines - as they say they've been 'dismissed and gaslighted' as anti-vaxxershttps://www.dailymail.co.uk/health/article-13386975/vaccine-prepare-body-unknown-coronaviruses.htmlScientists create new coronavirus jab that even works on viruses they haven't discovered yet in a bid to beat the next pandemicThe jab can protect against several coronaviruses already circulating in batshttps://youtu.be/WgoixKhPaMY?si=vWcDQTA3X7AEfqcwNew RNA vaccines coming - Dr. John Campbellhttps://www.dailymail.co.uk/health/article-13397133/Pfizer-agrees-settle-10-000-lawsuits-accusing-pharma-giant-hiding-cancer-risks-heartburn-drug-Zantac.htmlPfizer agrees to settle 10,000 lawsuits accusing pharma giant of hiding cancer risks of heartburn drug Zantachttps://www.biblegateway.com/passage/?search=1+Corinthians+10%3A24&version=CJB1 Corinthians 10:24No one should be looking out for his own interests, but for those of his fellow.https://www.biblegateway.com/passage/?search=Prov.29.16&version=CJBProverbs 29:16When the wicked flourish, wrongdoing flourishes; but the righteous will witness their downfall.
This Day in Legal History: Racist Restrictive Covenants Struck DownOn May 3, 1948, a significant legal decision was rendered by the United States Supreme Court, fundamentally altering the landscape of civil rights and property law. The case, Shelley v. Kraemer, addressed the pernicious practice of racially-restrictive covenants in real estate. These covenants were agreements embedded in the deeds of properties that prohibited the sale of these properties to individuals of certain races, most commonly African Americans.The Supreme Court's decision in Shelley v. Kraemer struck down the legal enforcement of these covenants, ruling that while private parties may enter into whatever agreements they choose, they cannot seek judicial enforcement of covenants that violated constitutional principles of equality. The Court held that such enforcement by state courts constituted state action and therefore was subject to the Equal Protection Clause of the Fourteenth Amendment.The background of the case involved an African American family, the Shelleys, who purchased a home in a neighborhood in St. Louis, Missouri. This neighborhood had an existing covenant that barred African Americans from owning property. When the Shelleys moved in, several of their white neighbors sought to enforce the covenant to prevent them from taking ownership.The Missouri Supreme Court had originally sided with the neighbors, ruling that the covenant was enforceable. However, the U.S. Supreme Court's decision reversed this ruling. Justice Fred M. Vinson, writing for the majority, emphasized that the enforcement of racially restrictive covenants by state courts amounted to a state action that denied equal protection of the laws.This landmark decision was a crucial step forward in the fight against institutionalized racism, particularly in housing. It reflected the growing judicial recognition of civil rights issues and set a precedent for future rulings related to racial discrimination. Moreover, Shelley v. Kraemer highlighted the judiciary's role in upholding constitutional rights against socially entrenched racial discrimination.The ruling did not, however, eliminate racially restrictive covenants overnight. Many neighborhoods continued to observe such agreements informally, and it wasn't until later legislative efforts, such as the Fair Housing Act of 1968, that such practices were comprehensively outlawed. Nevertheless, the Shelley v. Kraemer decision remains a pivotal moment in American legal history, celebrated for its affirmation of the principles of equality and justice enshrined in the U.S. Constitution.The Biden administration is set to implement a rule that will allow undocumented immigrants who arrived in the U.S. as children and are covered under the Deferred Action for Childhood Arrivals (DACA) program to receive subsidized health insurance through Obamacare. This rule, scheduled for release by the Department of Health and Human Services (HHS), will redefine "lawfully present" individuals to include DACA recipients, enabling them to access premium tax credits and cost-sharing reductions when purchasing plans from federal and state marketplaces beginning November 1, 2024.HHS Secretary Xavier Becerra emphasized the importance of this change, noting that over a third of DACA recipients currently lack health insurance. The inclusion of DACA recipients is expected to improve not only their health and wellbeing but also contribute positively to the overall economy. Additionally, the rule will permit these individuals to enroll in basic health programs similar to Medicaid in certain states, provided they earn no more than 200% of the poverty level.The Centers for Medicare & Medicaid Services anticipate that this adjustment could result in 100,000 previously uninsured DACA recipients gaining health coverage. This decision marks a significant shift from previous policies where DACA recipients were excluded from being considered "lawfully present" for insurance purposes due to the original rationale behind the DACA policy, which did not address eligibility for insurance affordability programs.The significant development in this story is the modification of the definition of "lawfully present" by the HHS to include DACA recipients. This change is crucial as it directly impacts the eligibility of these individuals for health insurance subsidies under Obamacare, a shift in policy that broadens access to healthcare for a previously marginalized group.DACA Immigrants Win Access to Obamacare Subsidies in HHS RuleIn a groundbreaking trial in Chicago, attorneys for Angela Valadez, an 89-year-old woman who developed colon cancer, argued that pharmaceutical companies GSK and Boehringer Ingelheim were aware that the heartburn medication Zantac could become carcinogenic under certain conditions but failed to alert the public. The lawyers contended that Zantac's active ingredient, ranitidine, could transform into a cancer-causing substance called NDMA if it aged or was subjected to high temperatures, and accused the companies of covering up the degradation of the pills by altering their appearance.GSK and Boehringer Ingelheim, the only defendants in this trial after other companies reached settlements, defended their product. They insisted that Zantac has been proven safe and effective through numerous studies and that no direct evidence links Zantac to Valadez's cancer, citing her other risk factors for the disease. The U.S. Food and Drug Administration had removed Zantac and its generic versions from the market in 2020 after detecting NDMA in some samples. Despite this, a significant legal victory came for the companies in 2022 when a judge dismissed about 50,000 claims, questioning the scientific backing of the assertion that Zantac could cause cancer. However, with more than 70,000 cases still pending, largely in Delaware, the issue remains a significant legal and public health concern. A newer version of Zantac with a different active ingredient is currently on the market, which does not contain ranitidine.GSK knew about Zantac cancer risk, attorneys tell jury in first trial | ReutersIn the ongoing criminal trial of former U.S. President Donald Trump in New York, a new defensive angle emerged as Trump's lawyer portrayed the hush money payment at the center of the trial as potentially extortive. The payment in question involved Stormy Daniels, real name Stephanie Clifford, who was reportedly paid to keep quiet about an alleged encounter with Trump prior to the 2016 presidential election.During the proceedings, defense attorney Emil Bove questioned Keith Davidson, Daniels' former lawyer, about his history with negotiating cash-for-dirt agreements with celebrities, hinting that Davidson's actions bordered on extortion. Trump's legal team appears to be focusing on undermining the credibility of prosecution witnesses like Daniels and Michael Cohen, Trump's former lawyer and fixer, who arranged the controversial $130,000 payment. Trump has denied any encounter with Daniels and pleaded not guilty to the charges of falsifying business records to conceal the payment.This trial aspect dovetails with previous testimony regarding Cohen's disappointment over not receiving a major governmental post after Trump's election victory. Cohen, who later disassociated from Trump and criticized him publicly, is expected to be a key witness. He has already served prison time for his role in the payment scheme.Moreover, the trial has seen further complications due to Trump's conduct outside the courtroom. Justice Juan Merchan has had to address violations of a gag order by Trump, who has been fined and could potentially face jail for continuing infractions. Trump has criticized the trial publicly, claiming it is an attempt to prevent his political comeback and alleging conflicts of interest by those involved in the trial.Trump's various legal troubles include other serious charges, such as attempting to overturn the 2020 election results and mishandling classified documents, adding layers of complexity to his current legal battles as he campaigns for the 2024 presidential election. These developments suggest a trial fraught with legal and political ramifications, with Trump's defense pushing back against what they suggest are questionable prosecutorial tactics and witness credibility.Trump trial hears Michael Cohen was 'despondent' he was denied a government post | ReutersTrump lawyer suggests hush money payment was extortion | ReutersThis week's closing theme is by Johannes Brahms.Johannes Brahms, born on May 7, 1833, in Hamburg, Germany, is one of the most revered figures in the history of classical music. His compositions span a wide range of genres, including chamber works, symphonies, and choral compositions. Brahms was known for his perfectionist approach, often taking years to refine his works to his satisfaction.Among his most celebrated creations is Symphony No. 1 in C minor, Op. 68. This symphony, which took Brahms about 14 years to complete, is frequently dubbed "Beethoven's Tenth" due to its stylistic similarities to Ludwig van Beethoven's symphonic work, especially the Ninth Symphony. Brahms's dedication to living up to Beethoven's legacy is evident in the meticulous structure and emotional depth of the piece.Symphony No. 1 was first performed in 1876, and since then, it has become a staple in the orchestral repertoire. It is particularly noted for its profound depth and complexity. The symphony unfolds over four movements, beginning with a dramatic and tense first movement that features a memorable timpani motif, which sets a somber and introspective mood. This is followed by a gentle and lyrical second movement, offering a stark contrast to the dramatic opening. The third movement, often considered the heart of the symphony, showcases Brahms's skill in thematic development and orchestral color. The finale is a triumphant resolution to the symphony's earlier tensions, culminating in a powerful and uplifting theme that echoes Beethoven's own symphonic climaxes.This week's closing theme features this masterful work by Brahms, inviting listeners to explore the depths of his musical genius. Symphony No. 1 stands not just as a nod to Beethoven's influence but as a significant original contribution to the symphonic form, marking Brahms's triumphant emergence as a composer of the first order in the orchestral domain.Without further ado, Brahm's Symphony No. 1 in C Minor, Op. 68 - III. Un poco allegretto e grazioso, enjoy. Get full access to Minimum Competence - Daily Legal News Podcast at www.minimumcomp.com/subscribe
Henry Simmons, a former judge and managing partner at Clifford Law Offices, joins Lisa Dent to talk about the first-ever trial, being held in Chicago, over claims that Zantac causes cancer. Follow The Lisa Dent Show on Twitter:Follow @LisaDentSpeaksFollow @SteveBertrand Follow @kpowell720 Follow @maryvandeveldeFollow @LaurenLapka
Szentkirályi Alexandra titokban majálisozott, de megtaláltuk, ahol aztán a macsóskodó Karácsonyról beszélt a Telexnek Telex 2024-05-01 12:20:42 Belföld Fidesz Gyurcsány Ferenc Telex Szentkirályi Alexandra Fidelitas A Fidesz főpolgármester-jelöltje fidelitasosokkal és a kormánymédiával piknikezett, ahol először meghallgattuk, hogy Gyurcsány. Aztán megkérdeztük tőle: kategorikusan ki tudja-e jelenteni, hogy nem lép vissza a választás előtt. "Minden brüsszeli döntésnél ülnek magyarok" 24.hu 2024-05-01 11:06:20 Belföld Belgium Interjú Brüsszel Európai Bizottság Nagykövet Régi-új vezető tért vissza az Európai Bizottság magyar képviseletéhez. Zupkó Gábor korábban hét évig vezette a bizottság magyarországi "nagykövetségét", és távozása után nem neveztek ki új állandó vezetőt. Most ismét visszatér. Az uniós csatlakozásunk évfordulójára interjúztunk vele. Hirtelen megszólalt az amerikai külügyminiszter a tűzszünetről Privátbankár 2024-05-01 12:10:00 Külföld USA Izrael Palesztina Gázai övezet Hamász Antony Blinken amerikai külügyminiszter szerint az Hamász iszlamista terrorszervezeten múlik a tavaly október 7-én a Gázai övezetbe hurcolt izraeli túszok kiszabadításáért folyó tűzszüneti tárgyalások sikere. Elemző Magyarországról: a választások után konszolidációs program jöhet vg.hu 2024-05-01 15:44:04 Belföld GDP Bruttó hazai termék Az S&P Global legfrissebb elemzése szerint a magyar költségvetés hiánya idén a GDP 5,3 százalékára rúg majd. Egymilliárdból indít programot a kormány a kávéházi cigányzene megőrzésére 444.hu 2024-05-01 12:19:31 Belföld Kávé Cigányság Magyar Turisztikai Ügynökség A Magyar Turisztikai Ügynökség elnöke szerint a cigányzene vendégélményt növelő turisztikai eszköz. Indul a rákkeltő hatásairól ismertté vált gyomorsavcsökkentő elleni első per Liner 2024-05-01 11:22:00 Külföld Gyógyszer Chicago Reflux Chicagóban veszi kezdetét a Zantac gyomorsavcsökkentő gyógyszer rákkeltő hatásairól szóló első per. A BeSocial sorrendje: Friderikusz, Bödőcs, Pottyondi Mínuszos 2024-05-01 12:10:43 Gazdaság Felmérés TikTok Facebook Bödőcs Tibor Friderikusz Sándor Többet nyomkodják a Facebookot, mint amennyi időt tévénézéssel vagy családi programokkal töltenek, szeretik a podcasteket, kezdenek rászokni a TikTokra. A BeSocial digitális ügynökség az 55 év feletti korosztályról készített, a “Szeniorok a neten” elnevezésű online felmérése szerint “Bár a klasszikus média még sokkal jobban jelen van a mindennapjai Kocsis Máté komoly veszélyre mutatott rá az ellenzékkel kapcsolatban Magyar Hírlap 2024-05-01 13:05:00 Belföld Kampány Kocsis Máté Mint mondja, lemásolja a baloldal a két évvel ezelőtt sem működő kampányát, csak mást tolnak a kirakatba. A júliusi olimpia miatt számolják fel a párizsi sátortáborokat HírTV 2024-05-01 12:09:00 Külföld Polgármester Olimpia Bevándorlás Párizs Tiltakoznak francia nagyvárosok polgármesterei amiatt, hogy a hatóságok Párizsból, az olimpia helyszíneinek közeléből vidékre költöztetnek át illegális bevándorlókat. Különleges buszra ülhetnek a magyarok Vezess 2024-05-01 11:22:25 Autó-motor Németország Technikai szempontból érdekes buszt tesztelhetnek az utasok a következő néhány napban. Az újdonság Németországból érkezett hazánkba. Teljes adóreform kell az EU szerint, túl sok az igazságtalanság Portfolio 2024-05-01 17:00:00 Gazdaság Európai Bizottság Koronavírus Úgy ajánlásokat fogalmazott meg az Európai Bizottság az adórendszerek teljes átalakítására. A javaslatok többek között magukban foglalják a rendszeres ingatlanadók bevezetését vagy a már meglévők növelését és a munkaadói terhek csökkentését, különösen az alacsony jövedelemű adófizetők esetében. Az ajánlások célja a zöld átmenet elősegítése, a Covid Akkora gólpasszt adott, hogy a csapattársa is meghajolt előtte, majd azt mondta: nem volt semmi különös 444.hu 2024-05-01 10:17:59 Foci Bajnokok Ligája Toni Kroos gólpassza a Bajnokok Ligája elődöntőjében igazi egy mester munkája. A kezével jelzett, aztán úgy zúzta porrá az ellenfél védelmét, mintha ez lenne a világ legtermészetesebb dolga. Ő lehet a közeljövő egyik legjobb hatosa, de nem Erik ten Hag irányítása alatt Büntető.com 2024-05-01 11:27:01 Foci Hollandia Anglia Manchester Premier League Manchester United A 19 éves Kobbie Mainoo az előző idényben csupán tizenegy percet tölthetett a pályán a Premier League-ben. Ebben a szezonban viszont már megadta számára a lehetőséget Erik ten Hag, a Manchester United menedzsere. Egyelőre nem nyújt kiemelkedőt, de ebben nagy szerepe van a holland szakvezetőnek és a manchesteriek kontroll nélküli játékának. Az angol Hétvégére is jut a zivatarokból Kiderül 2024-05-01 13:41:44 Időjárás Hétvége Csapadék A legtöbb helyen pénteken számíthatunk csapadékra, de még a hétvégén is az erőteljes gomolyfelhő-képződésből előfordulhatnak záporok, zivatarok. A további adásainkat keresd a podcast.hirstart.hu oldalunkon.
This Day in Legal History: MLK Assassinated On this day in legal history, April 4, 1968, the civil rights movement faced a tragic moment when Martin Luther King Jr., an emblematic leader advocating for nonviolent resistance against racial discrimination, was assassinated in Memphis, Tennessee. King's untimely death occurred at the Lorraine Motel, a location that has since been etched into the national consciousness as a site of profound loss and reflection. His assassination sparked an outpouring of grief and anger across the United States, leading to widespread riots in over 100 cities and a national mourning that underscored the deep divisions and tumultuous struggles of the era.In the immediate aftermath, James Earl Ray, a fugitive from the Missouri State Penitentiary, was identified and later apprehended at London's Heathrow Airport, marking the beginning of a controversial and complex legal saga. Ray was charged with King's murder, and in a move that avoided a potentially explosive trial, he entered a guilty plea, receiving a 99-year prison sentence. However, Ray recanted his confession three days later, claiming he was a pawn in a broader conspiracy, a declaration that fueled ongoing debates and investigations into the assassination.The legal reverberations of King's assassination extended beyond the pursuit and conviction of his killer. In response to the national tragedy, Congress was galvanized to enact further civil rights legislation, including the Fair Housing Act of 1968, which sought to eliminate housing discrimination against minorities, a cause King had fervently championed. Moreover, the assassination intensified efforts to ensure equal rights and justice, inspiring legal challenges and reforms that continued to shape the civil rights landscape.King's legacy, deeply rooted in his pursuit of justice and equality through peaceful means, has had a lasting impact on American legal and social fabric. His vision and teachings continue to inform contemporary movements and legal principles, demonstrating the enduring power of nonviolent resistance in the face of injustice. On this day, we remember not just the loss of Martin Luther King Jr. but the enduring influence of his life's work on the quest for civil rights and legal equality in America.Sanofi has agreed to settle approximately 4,000 lawsuits in the United States alleging that the heartburn medication Zantac, which the company previously marketed, is linked to cancer. This agreement aims to resolve most of the legal actions against Sanofi in U.S. state courts, except for those in Delaware, where the bulk of cases are still pending. Despite not admitting liability, Sanofi cited the desire to avoid the costs and distractions of ongoing litigation as reasons for the settlement, the financial terms of which were not disclosed. The company still faces around 20,000 additional lawsuits in Delaware, with both sides awaiting a crucial judicial decision on the scientific validity of the claims that Zantac causes cancer. This situation follows a 2022 victory for the drugmakers when a judge dismissed 50,000 similar lawsuits on the grounds that the plaintiffs' expert opinions lacked solid scientific support. Amidst ongoing litigation, Sanofi has introduced Zantac360, a reformulated version of the medicine, following the discovery of NDMA, a carcinogenic chemical, in some Zantac pills which led to its market withdrawal in 2020 by the FDA's request.Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts | ReutersA New York judge has rejected former U.S. President Donald Trump's request to delay his upcoming trial over charges related to hush money payments until after the U.S. Supreme Court reviews a separate case regarding presidential immunity. The trial, set for April 15, involves allegations of falsifying business records to conceal a payment made to silence claims of a past sexual encounter ahead of the 2016 election, an encounter Trump denies. Trump's legal team had argued for the delay, citing the relevance of a Supreme Court case set for April 25 that will consider Trump's immunity claims related to actions taken during his presidency. However, Justice Juan Merchan dismissed the delay request, noting Trump's late invocation of presidential immunity as a defense.This trial in New York could potentially be the only one of four criminal indictments against Trump to proceed before the November election, where Trump is a Republican candidate. Additionally, Trump's lawyers have sought to postpone the trial due to concerns over prejudicial pre-trial publicity, though the court has not yet ruled on this matter. The Manhattan District Attorney's office has opposed the delay, arguing that unbiased jurors can be selected despite the extensive media coverage, much of which, they claim, Trump instigated. The decision by the Supreme Court to hear Trump's appeal in a federal case has already delayed that trial, highlighting the unprecedented nature of a former U.S. president facing criminal proceedings.Trump loses bid to delay hush money trial until US Supreme Court review | ReutersThe Massachusetts Supreme Judicial Court is considering class action lawsuits against the collection of website users' browsing data without consent, a practice allegedly involving tools from Meta Platforms and Google. This consideration interprets a 1960s eavesdropping prohibition, originally intended for phone and telegraph communications, as applicable to modern internet tracking. The court is deliberating on whether to allow two proposed class actions to proceed, which accuse two hospitals of violating the Massachusetts Wiretap Act by using third-party technologies that share users' activities with companies like Google and Meta. The possibility of making any ruling prospective was suggested by justices, to avoid penalizing past tracking activities not previously identified as illegal under the law.The case arises from complaints by Kathleen Vita, who alleges that her visits to the Beth Israel Deaconess Medical Center and New England Baptist Hospital websites resulted in the unauthorized sharing of her browsing data. A trial court judge previously determined that the wiretap law does cover such internet tracking, a decision challenged by the hospitals' legal representation as an "absurd" extension of the decades-old statute. However, the Supreme Court's prior extension of the law's coverage to cell phones and text messages in 2013 supports the argument for its applicability to internet data collection.The lawsuit has drawn attention from industry groups like the U.S. Chamber of Commerce and National Retail Federation, concerned about the implications for countless website operators using common analytics tools. Despite similar cases being dismissed in other states, the Massachusetts case, bolstered by a prior $18.4 million settlement in a similar lawsuit, could set a precedent. The defense argues that the use of such data-gathering technologies falls under a business exemption, a claim met with skepticism from the court regarding its relevance to hospital operations. The court's final decision may include prospective measures to allow website operators to adjust practices accordingly, highlighting the case's potential surprise and impact on the broader web development and ownership community.Massachusetts top court considers allowing website tracking class actions | ReutersThe estate of the late comedian George Carlin settled a lawsuit against podcasters Will Sasso and Chad Kultgen, who used AI to create a faux Carlin comedy special and release it on YouTube. As part of the agreement, the podcasters from "Dudesy" will remove the AI-generated content and are barred from using Carlin's image, voice, or likeness without permission. This legal battle highlights the challenges at the intersection of AI technology, copyright law, and post-mortem publicity rights, marking one of the first cases to address these issues head-on. The lawsuit, filed by Carlin's estate in the US District Court for the Central District of California, underscores the growing concerns over the misuse of AI to replicate individuals' likenesses. Kelly Carlin, George Carlin's daughter, expressed hope that this case would serve as a cautionary tale about the potential dangers of AI and the importance of establishing protective measures. The settlement, though largely confidential, is seen as a necessary step in addressing the legal implications of advancing AI technologies in the realm of intellectual property and personal rights.George Carlin Estate Settles AI-Made Comedy Special Lawsuit (1) Get full access to Minimum Competence - Daily Legal News Podcast at www.minimumcomp.com/subscribe
Nurses Out Loud with Nurse Michele, RN – We delve into the drawbacks of Ozempic for weight loss and its potential long-term health impacts. We also explore the recent interview by Tucker Carlson with the Florida Surgeon General regarding COVID-19 vaccine concerns. Additionally, we expose pharmaceutical corruption, including the Zantac scandal, and discusses DEI solutions in the workplace. Tune in for these critical health...
Nurses Out Loud with Nurse Michele, RN – We delve into the drawbacks of Ozempic for weight loss and its potential long-term health impacts. We also explore the recent interview by Tucker Carlson with the Florida Surgeon General regarding COVID-19 vaccine concerns. Additionally, we expose pharmaceutical corruption, including the Zantac scandal, and discusses DEI solutions in the workplace. Tune in for these critical health...
Jennifer Johnson talks about the recently published GSK results, which showed strong growth, but the ongoing Zantac litigation is hanging over the shares. The team also touch on the prospects of rival pharma companies AstraZeneca and Indivior.Our US-based journalist Arthur Sants joins from New York to unpack the growth, capex and future returns worries investors may have about the Magnificent Seven.It's then on to food producers AG Barr and Premier Foods with Mark Robinson, who shares news of trading updates, a new CEO sourced from an unlikely sector, and the prospects for growth.Last on the agenda, Mark shares the thinking behind his latest feature on regulation and how investors can get involved with the companies using it to their advantage.Dan Jones is joined by Jennifer Johnson, Alex Newman, Arthur Sants and Mark Robinson.Timestamps1:34 GSK and pharmaceutical firms15:20 US Tech stocks 28:58 AG Barr and Premier Foods36:22 RegulationMentioned in this episodeSemiconductor industry split between AI and the restGSK's RSV vaccine success makes its shares look cheapIrn Bru maker AG Barr buoyed by new subsidiariesThree companies benefitting from more regulationFTSE 350 Review: The drinks brands likely to grow in a struggling marketFTSE 350 Review: Will GSK replace Astra as the investor favourite?FTSE 350 Review: Software companies scramble to find AI uses Hosted on Acast. See acast.com/privacy for more information.
What drives a legal team to succeed against all odds in high-stakes mass tort litigation? In this captivating episode of The Heart of Law, join our intrepid host, Mirena Umizaj, as she welcomes Attorney Jennifer A. Moore, the founder of Moore Law Group PLLC, to explore her transformative journey from personal injury law to the forefront of mass tort litigation. Embark on an exploration of resilience and justice as Attorney Jennifer A. Moore shares her pivotal role in the landmark Monsanto trial, a victory that not only shaped her career but also underscored her commitment to accountability in major legal battles, including the ongoing Zantac litigation. At the helm of Moore Law Group, PLLC, Jennifer A. Moore has earned a distinguished reputation for her unwavering advocacy on behalf of individuals nationwide suffering from injuries caused by defective products, medical malpractice, and motor vehicle accidents. With a legal career spanning over two decades, Jennifer A. Moore's record of securing numerous multi-million-dollar verdicts and settlements has cemented her status as a formidable figure in class and complex litigation. Her dedication to justice was resoundingly demonstrated by successfully trying the only federal court case involving Roundup weedkiller, which resulted in an $80 million verdict against Monsanto and led to settlements exceeding $10 billion for thousands of victims. Beyond her legal achievements, Jennifer A. Moore's leadership extends to empowering future female leaders through her work with Emerge Kentucky. As its founder and past board chair, she has played a crucial role in training over 250 women, 42 of whom are currently serving in office. As the dialogue unfolds, Mirena delves into Jennifer A. Moore's early inspiration to become a lawyer, a spark ignited during her elementary school years by her aunt's legal journey and the historic appointment of Sandra Day O'Connor to the Supreme Court. Her early fascination with law matured into a steadfast commitment, guiding her through law school and subsequently to a judicial clerkship with the Sixth Circuit, an enriching experience she recommends every law student undertake. As the conversation deepens, Mirena inquiries about the pathway to success in mass tort litigation, prompting Jennifer A. Moore to emphasize the importance of pursuing a career "doing something you love." She candidly discusses her personal commitment to representing cancer victims, a path shaped by her own experiences and fueled by an earnest desire to seek accountability from those responsible. Her dedication to this cause, deeply intertwined with her professional ethos, exemplifies the powerful impact of aligning personal values with legal practice. Shifting focus, Mirena touches upon a seminal moment in Jennifer A. Moore's career: the trial against Monsanto, a case that not only marked a significant victory for her clients but also profoundly altered the trajectory of her career. Jennifer A. Moore reflects on the trial's intensity, paralleling it with her childhood experiences of riding horses with her grandfather, who instilled in her the tenacity to rise after every fall and to not let fear be apparent. This lesson became pivotal in her legal approach, especially in front of a jury, where she learned the importance of exuding confidence, understanding that just like a horse, a jury can sense fear. Moreover, Mirena inquiries about the evolving landscape of mass torts, highlighting the dual impacts of digital advertising and private equity in the sector. In response, Jennifer A. Moore stresses the importance of thorough due diligence, consistent and effective client communication, and cultivating professional relationships, outlining these as key strategies for adeptly navigating the terrain. As their conversation draws to a close, the focus shifts to the recent Zantac litigation, where Jennifer A. Moore provides an update on the significant advancements and challenges. She details the dismissal of cases in the MDL and their ongoing appeal in the 11th circuit, expressing frustration over the court's handling of scientific evidence. Her commitment to her work is unmistakably clear as she discusses working through the holiday season to meet key deadlines. This dedication is part of her preparation for a challenging year ahead, including multiple trials in California and a Daubert hearing in Delaware, exemplifying her relentless pursuit of justice and unwavering commitment to her clients.
In this LegalCast episode, host Mark York engages in a deep dive into the world of mass torts with Joe Fantini from Rosen Injury Lawyers. Joe's extensive legal journey, from a law clerk in Philadelphia's Court of Common Pleas to transitioning between defense and plaintiff representation, provides a rich backdrop for the discussion. He emphasizes the diversity in firms engaging in mass torts, highlighting the opportunities for both large and small-scale firms to make a substantial impact. Throughout the conversation, Joe stresses the collective strength of legal alliances, emphasizing how firms banding together can effect significant change against corporate giants, benefiting affected individuals and reshaping market practices. He sheds light on ongoing cases in the Philadelphia Court of Common Pleas, such as Roundup and Zantac, underlining the importance of venue familiarity in these litigations. Joe shares insights into compiling and disseminating complex tort-related information for wider comprehension, extending a helping hand to fellow attorneys navigating these intricate cases. The conversation navigates ethical concerns within the legal and marketing spheres, highlighting the need for genuine relationships with lead-generating vendors and anticipating increased regulation for industry integrity. Amidst newer, uncertain cases, Joe pinpoints Roundup and Hernia Mesh as promising litigations due to their defined criteria and ongoing developments, offering valuable guidance for firms considering involvement in these cases. https://roseninjurylawyers.com/
For our 51st podcast episode, I discussed a contensious topic in the neonatal world, Gastroesophageal Reflux (GER) and Gastroesophageal Reflux Disease (GERD). Although it is a common occurrence amongst all infants, the lack of updated, clear, and consistent diagnostic and management recommendations remains, especially for the NICU population. Due to my personal and professional experiences, it is difficult for me to have one solid stance on the topic. As a former NICU nurse, I saw so many infants experience reflux. As a NICU parent, my son William, struggled with reflux once we brought him home and yes, at that time, it was managed with medication. And finally, now as a Neonatal Nurse Practitioner, I am more knowledgeable about what the evidence does and does not show regarding reflux and I understand its complexity. So I can fully appreciate how nurses advocate for their patients. I also completely acknowledge the internal battle parents endure as they helplessly watch their baby grapple with reflux and its associated symptoms, and I also embrace what the research has shown and why providers do not hastily start infants on reflux medications. Tune in now to learn the difference between Gastroesophageal Reflux and Gastroesophageal Reflux Disease, some common symptoms, and how it is typically diagnosed. Be amazed as I debunk some of the common myths and conditions that are thought to be associated with GERD. Additionally, listeners will also walk away with a better understanding of the most up-to-date recommendations for the management of GER and GERD including non-pharmacological and pharmacological treatments. So sit back and get ready to be empowered as we discuss Gastroesophageal Reflux. Free Resource: https://empoweringnicuparents.com/ger/Dr. Brown's Medical: https://www.drbrownsmedical.comOur NICU Roadmap: A Comprehensive NICU Journal: https://empoweringnicuparents.com/nicujournal/NICU Mama Hats: https://empoweringnicuparents.com/hats/NICU Milestone Cards: https://empoweringnicuparents.com/nicuproducts/Newborn Holiday Cards: https://empoweringnicuparents.com/shop/Empowering NICU Parents Show Notes: https://empoweringnicuparents.com/shownotes/Episode 51 Show Notes: https://empoweringnicuparents.com/episode51Empowering NICU Parents Instagram: https://www.instagram.com/empoweringnicuparents/Empowering NICU Parents FB Group: https://www.facebook.com/groups/empoweringnicuparentsPinterest Page: https://pin.it/36MJjmH
A while back, we did a mini-series on peptides and sexual wellness. We covered PT-141 (bremelanotide), a peptide therapy used to help women and men with low sex drive. And Kisspeptin-10, a peptide that helps with increased arousal and may help with infertility. But we really didn't focus on what causes a low sex drive. So today, we'll touch on the possible mental and physical causes that may affect your sex drive, but we'll focus on medications that may lead to a decreased interest in sex. It's important to know that a low sex drive can affect both men and women. Medical conditions like depression, hypothyroidism, diabetes, and high blood pressure, may all cause a low sex drive. Even hormonal changes (e.g., during pregnancy, after childbirth, or while breastfeeding) can decrease interest in sex. And some people who use alcohol, have relationship issues, or certain infections (e.g., vaginal yeast infections, urinary tract infections) have a low sex drive. Certain medications may cause low sex drive as a side effect. But remember that not everyone taking certain medications will have the same issues. Some antidepressants and antipsychotics are more likely to cause a low sex drive than others. For example, selective serotonin reuptake inhibitors (SSRIs) like Paxil, Zoloft, and Proac are more likely to cause a low sex drive than Wellbutrin or Remeron. While older antipsychotics like Haldol, used to treat schizophrenia and bipolar disorder, are more likely to cause a low sex drive than Risperdal. Benzodiazepines like Xanax, Ativan, and Valium, used to treat anxiety and seizure disorder, can lower your sex drive. Many people with heart failure report having a low sex drive. This is because people with heart failure need different medications to reduce how fast or hard their heart has to work and medications that get rid of extra fluid. Unfortunately, some heart failure medications like Digoxin, Spironolactone, beta-blockers, and other water pills like hydrochlorothiazide can lower their sex drive. Acid reflux or "heartburn" happens when stomach acid travels back into the esophagus. And people who take medications for "heartburn" (e.g., Pepcid and Zantac) have reported a lower sex drive. Even medications that affect sex hormones (e.g., estrogen, testosterone, and progesterone) can decrease libido. Examples of these medications include birth control and Lupron (used to treat prostate cancer). And lastly, people who use opioids like Norco and Ultram to treat pain can also have a lower sexual desire. How to improve sex drive caused by medications? Always talk to your healthcare provider first. They can determine if your low sex drive is due to your medications or if there's another cause, like an infection or hormonal changes. If your medication is causing a low sex drive, your healthcare provider may have you stop the medication if it's not needed. Or they may switch you to an alternate medication that doesn't cause a low sex drive. But don't stop your medication without speaking to your healthcare provider first. Your healthcare provider may suggest other medications or peptides like PT-141 or Kisspeptin-10. What is PT-141? PT-141 (bremelanotide) is a melanocortin receptor agonist peptide. Melanocortin is a natural hormone in your body that works on receptors in your brain and nervous system to cause sexual arousal and influence sexual behavior. However, we don't know exactly how it works to improve sex drive. It can also work on receptors in cells that produce skin color (melanocytes). You may know PT-141 as Vyleesi. This medication was originally FDA-approved in 2019 to help low sex drive in women who haven't gone through menopause yet. While it's not approved for low sex drive in men, some may use it off-label. In these cases, men also use PT-141 to help improve erections, libido, sex drive, and performance. What is Kisspeptin-10? Kisspeptin-10 is a neuropeptide involved in reproduction, sexual behavior, and sexual attraction. It helps increase activity in the brain associated with sexual attraction and arousal. Kisspeptin-10 also stimulates the hypothalamus to release gonadotropin-releasing hormone (GnRH), which in turn signals the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones play a role in the production of both testosterone and estradiol. Thanks again for listening to The Peptide Podcast. You can find more information at pepties.com. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media. Have a happy, healthy week! Pro Tips We're huge advocates of using daily collagen peptide supplements in your routine to help with skin, nail, bone, and joint health. But what do you know about peptides for health and wellness? Giving yourself a peptide injection can be scary or confusing. But we've got you covered. Check out 6 tips to make peptide injections easier. And, make sure you have the supplies you'll need. This may include syringes, needles, alcohol pads, and a sharps container. They work to kill bacteria (bactericidal) by preventing them from making their own protective coating in your body.
Private Medical physicians Dr. Jordan Shlain and Dr. Hela Barhoush are joined by David Light, founder and CEO of Valisure. Started to investigate batch variability in pharmaceuticals, the independent lab has found carcinogens in brand name drugs like Zantac, aerosols like antiperspirants and dry shampoo, and other everyday products. The doctors discuss how medications and products are made, how and if they are tested along the supply chain, and the role of the FDA. Furthermore, they will illuminate how to be a smarter consumer as it pertains to your health. We hope this episode inspires you to think differently about your health and the healthcare system. Please subscribe to our feed and our bimonthly medical dispatch.
One may assume that a socialized healthcare system, in which the government pays for the majority of medical expenses, would be more concerned to prevent illnesses in the first place. Nevertheless, Dr. Max Gulhane, a general practice registrar, describes the Australian healthcare system as one that operates more like the profit-driven healthcare system of the US. The change in the population's diet and nutrition - one that promotes eating more grains, more bread, and more carbohydrate consumption - has led to an increase in the prevalence of metabolic illnesses. Yet despite the overwhelming support from credible studies that a low-carb diet helps with disease reversals, it still isn't widely accepted.Listen to Dr. Max Gulhane as he talks about animal-based diets as a key to reversing chronic diseases, why doctors are trapped in a system that heavily favors disease management more than disease reversal, and how pharmaceutical industries are weaponizing science.Quick Guide:0:50 Introduction07:17 The comparison of the Australian diet and the American diet11:48 Availability of lambs14:33 Nutritional reason to eat lambs or beef16:15 The state of obesity and diabetes in Australia21:34 What's the community's response toward the low-carb diet26:35 A look at the US and Australia's healthcare system40:14 Glaxo has known Zantac is linked to causing cancer 45:50 Science being weaponized by pharmaceutical industries48:25 Closing and contactsGet to know our guest:Dr. Max Gulhane is an Australian physician who practices family medicine. He advocates animal-based diets for metabolic health and regenerative farming. He also hosts a podcast called Regenerative Health.“Perhaps as long as you have someone in between your relationship with the patient and the doctor, in our case, Medicare, which is a government-funded health care system, who pays us as GPs to administer care to our patients, until there is, I guess, more of a direct relationship with us in the patient, you're gonna get, I guess, outcomes or treatment outcomes that aren't necessarily directed at the patient's disease and reversing the patient's disease. So yeah, no, it's not very land down here from a disease reversal point of view by any means.” - Dr. Max GulhaneConnect with him:https://linktr.ee/maxgulhanemdEmail: regenerativehealth@proton.me Episode snippets:08:32 - 09:57 The common Australian diet14:45 - 15:50 Lamb is nutritionally better than beef16:33 - 17:54 The higher BMIs are now evident in younger people22:41 - 23:10 - The patients are not benefitting from the advice they're given24:43 - 25:25 - A diet that reverses diabetes, but is offensive to the status quo27:47 - 28:55 - What influences the healthcare system37:09 - 39:03 - A financial stake in their health Contact Stay Off My Operating TableTweet with us: Dr. Ovadia: @iFixHearts Jack Heald: @JackHeald5 Learn more: Get Dr. Ovadia's book Stay Off My Operating Table on Amazon. Take Dr. Ovadia's metabolic health quiz: iFixHearts visit Dr. Ovadia's website: Ovadia Heart Health visit Jack Heald's website: CultYourBrand.com Theme Song : Rage AgainstWritten & Performed by Logan Gritton & Colin Gailey(c) 2016 Mercury Retro Recordings
Welcome to the Neoborn And Andia Human Show's electrifying new episode! This week, we tackle some hard-hitting topics that'll make you want to tune in and listen up. First up, we discuss why rolling over to oppressors and overlords is a big no-no, and how acting out of fear can lead to suffering and ghettos. We also delve into the importance of belonging and how Gen Z can change their ways for the better.Next, Professor Andia enlightens us on hedonism and the power of DMTs and magic mushrooms. We then review a great live performance by The Unlimited Star, followed by a discussion on books being banned for no apparent reason and the absurdity of wrongthink Britain.We also uncover the shocking truth behind Zantac by GlaxoSmythKline and how it has been killing thousands of people for 40 years with its potent carcinogen. Our conversation then shifts to the loss of freedom of speech and religion in Canada, and how China is reshaping the country.To lighten the mood, we have a quick round of Battle of Jokes, followed by a discussion on the serious problems of Gen Z and how troubles in relationships can lead to wars. What's more, you may hear a fresh take on an Emily Dickinson's poem in a newer gown.Tune in to the Neoborn And Andia Human Show for a thought-provoking, entertaining, and electrifying episode that'll leave you wanting more! Don't miss out on the musings and sketches of these Two Purple Rabbits, Neoborn Caveman and Andia.Supporting Purple Rabbits!...................................... Hosted on Acast. See acast.com/privacy for more information.
R. Brent Wisner serves as the managing partner of Wisner Baum (previously Baum Hedlund Aristei & Goldman) and heads up the firm's state and federal involvement with Zantac litigation. Brent personally oversees the firm's pharmaceutical class action litigation, toxic-tort injuries, and consumer fraud litigation. Wisner began gaining notoriety in 2017 after serving as Co-lead Trial Counsel in litigation against GlaxoSmithKline (GSK) for the drug Paxil, yielding a $3 million verdict. A year later, Wisner began litigation against Monsanto Roundup, earning plaintiffs over $2.424 billion in damages across three plaintiff lawsuits–and earning Brent the title of youngest attorney to earn a billion-dollar settlement. Trial Lawyer Magazine named Brent to their 2019 list of “America's 50 Most Influential Trial Lawyers,” and National Trial Lawyers awarded him “Civil Plaintiffs Trial Lawyer of the Year.” The National Law Journal also named Brent to both 2019 lists of “America's 50 Most Influential Trial Lawyers” and “Winning Litigators, Titans of Industry.” Law360 awarded Brent the title of “MVP of the Year” in In 2020 for Products Liability and the National Law Journal and American Law Magazine inducted him into the Verdicts Hall of Fame. In 2021, Brent was awarded “West Trailblazer” by The American Lawyer, and Mass Torts Made Perfect awarded him with the “Clarence Darrow Award.” Most recently, The Litigation Counsel of America (LCA), a trial lawyer honor society, hand-picked Brent to receive the title of Associate Fellow in 2022 for his achievements as a leader across multiple dockets and his ethical commitment to plaintiff law. Brent currently maintains heavy involvement in Ranitidine litigation (Zantac), serving as Co-Lead Plaintiffs' Liaison Counsel for the Ranitidine Product Cases (MDL No. 2924) and Co-Chair of the American Association for Justice's Zantac Litigation Group. Brent remains extremely active in the legal community and regularly presents at legal conferences, such as MTMP, AAJ, HarrisMartin and CAALA on Zantac litigation. Brent Social Media LinkedIn - https://www.linkedin.com/in/r-brent-wisner-94046458/ Bio - https://www.wisnerbaum.com/attorneys/r-brent-wisner/ Wisner Baum Social Media LinkedIn - https://www.linkedin.com/company/wisnerbaum/ Facebook - https://www.facebook.com/BaumHedlund Twitter - https://twitter.com/WisnerBaum Remember to subscribe and follow us on social media… LinkedIn: https://www.linkedin.com/company/mass-tort-news Twitter: https://www.twitter.com/masstortnewsorg Facebook: https://www.facebook.com/masstortnews.org
A new survey from the Centers for Disease Control and Prevention finds that teenagers, particularly girls, are reporting all-time high rates of violence and profound mental distress. Meanwhile, both sides in the abortion debate are anxiously waiting for a district court decision in Texas that could effectively revoke the FDA's 22-year-old approval of the abortion pill mifepristone. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN's chief Washington correspondent, Julie Rovner, to discuss these issues and more. Click here for a transcript of the episode.Plus, for “extra credit” the panelists suggest health policy stories they read this week that they think you should read, too:Julie Rovner: NPR's “Is the Deadly Fungi Pandemic in ‘The Last of Us' Actually Possible?” by Michaeleen Doucleff. Alice Ollstein: The New York Times' “Childbirth Is Deadlier for Black Families Even When They're Rich, Expansive Study Finds,” by Claire Cain Miller, Sarah Kliff, and Larry Buchanan. Interactive produced by Larry Buchanan and Shannon Lin. Joanne Kenen: NPR's “In Tennessee, a Medicaid Mix-Up Could Land You on a ‘Most Wanted' List,” by Blake Farmer. Sandhya Raman: Bloomberg Businessweek's “Zantac's Maker Kept Quiet About Cancer Risks for 40 Years,” by Anna Edney, Susan Berfield, and Jef Feeley. Hosted on Acast. See acast.com/privacy for more information.
Bloomberg News US Economy Reporter Reade Pickert, explains how a yearslong decline in response rates for many of the surveys US government agencies use to compile economic data is a worrying development. Bloomberg Businessweek Editor Joel Weber and Bloomberg News Health Care Reporter Anna Edney provide the details of Anna's Businessweek Magazine story Zantac's Maker Kept Quiet About Cancer Risks for 40 Years. Bloomberg Intelligence Senior Tech Industry Analyst Mandeep Singh discusses Airbnb shares jumping on Wednesday after an outlook that shows robust travel demand. And we Drive to the Close with Sameer Samana, Senior Global Market Strategist at Wells Fargo Investment Institute.Hosts: Carol Massar and Madison Mills. Producer: Paul Brennan. See omnystudio.com/listener for privacy information.
On this week's episode, Vodafone is under the spotlight as it's problems in Europe continue. Is there much they can do in the face of big cash flow demands, rising inflation, sluggish growth?Next up it's a trip on the management merry-go-round. Over 20 per cent of FTSE 100 companies changed CEOs last year. Is this just a random datapoint, a sign of post-pandemic fatigue, or perhaps moving out ahead of the higher-rate era? Our panel discusses.Finally it's GSK chat with the IC's pharma writer Jennifer Johnson. With concerns around their Zantac drug, are investors lacking faith in the GSK pipeline?Dan Jones hosts Alex Newman, Julian Hofmann and Jennifer Johnson. Hosted on Acast. See acast.com/privacy for more information.
Download the cheat: https://bit.ly/50-meds View the lesson: Generic Name ranitidine Trade Name Zantac Indication duodenal ulcers, GERD, heartburn, esophagitis, GI bleed Action inhibits action of histamine in gastric parietal cells, decreases gastric acid secretion Therapeutic Class antiulcer agents Pharmacologic Class histamine H2 antagonists Nursing Considerations • may cause arrhythmias, agranulocytosis, aplastic anemia, confusion • assess abdominal pain • monitor for blood in stool • monitor CBC
Our weekly recap and preview for next week features AMC Entertainment Holdings, Endo International, Reverse Mortgage Funding and the Zantac multidistrict litigation. This week, with borrowing rates hovering around 30-year highs, we feature a replay from The Reorg Primary View series, where Christopher Maloney, mortgage strategist at Bank of Oklahoma Financial, and Reorg's James Holloway discuss stresses in the housing market, mortgage lenders and Fed policy. If you are not a Reorg subscriber, request access here: go.reorg-research.com/Podcast-Trial We're looking for feedback to improve the podcast experience! Please share your thoughts here: www.research.net/r/Reorg_podcast_survey
Show Notes and Links: https://www.chrisbeatcancer.com/attorney-brent-wisner-winning-against-monsanto-and-big-pharma
Jim Cramer and David Faber led off the show with another inflation report extending the market rally: The Producer Price Index for July fell unexpectedly month-on-month for the first time in more than two years, though still up 9.8% from a year ago. The anchors also reacted to Disney shares surging on quarterly results, driven by record theme park revenue, bigger-than-expected Disney+ subscriber growth and plans for a new pricing structure -- including a hike in streaming subscription fees. Devon Energy CEO Rick Muncrief joined the program. Heading into Thursday's trading session, Devon shares were up more than 280% since the beginning of 2021. Also in focus: Drugmakers GSK and Sanofi take a hit on litigation concerns surrounding heartburn drug Zantac.
Our guest today is Je Yon Jung, senior counsel at May Lightfoot. Je Yon has more than two decades of legal experience, including work in consumer protection, civil rights, discrimination, and financial services. What all of this diverse work has in common is a dedication to serving communities that have been left out or abused by the legal and justice systems.Je Yon emigrated to the United States with her family as a small child. From her earliest memories, she was certain that she wanted to be a lawyer. Though the patriarchal tradition of Korean culture left her with little support for this ambition, Je Yon's determination landed her in the Department of Justice only one year out of law school. Her work has now branched into the mass tort space with the complex and ongoing Zantac litigation.In this interview, we'll discuss how Rodney King changed the trajectory of Je Yon's career, the value of friendships, and how she came to know so much about soccer.Check out our sponsors!Hennessey DigitalMilestone FoundationTrial School7 Figure CasesJoin our Better Together LinkedIn Group
Most medications people take on the regular have a nutrient that it interacts with. Why is this important? Zantac or Prilosec could eventually make you feel super tired and run down? How? Iron needs an acidic enivironment to be absorbed and without that stomach acid, low iron absorption can lead to anemia. Anemia leaves you feeling run down. Anemia can negatively impact the thyroid hormone and their conversion. In today's episode, I'm sharing a few other common medications and the nutrients that are affected (plus how it can impact your body). Join me, Nicole Eichinger, in another episode of the Nutrition's My Life Podcast.
Mass Torts Made Perfect (MTMP) is known for its terrific network opportunities among law firms, marketers, and other legal industry professionals, excellent entrainment, and extracurricular activities. At the heart of all these activities are rich seminars with critical information that no one serious about mass torts should miss. This week's podcast features Grace giving us a rundown of all the major updates and insights that were shared at this Spring Session of MTMP. From the expansion of CPAP to the segmentation of baby formula cases to the new qualifiers for Zantac. Furthermore, Liel looks at historical marketing data for each of these torts to assist you in making judgments about your mass torts portfolio based on current costs per acquisition. Resources mentioned in our episode: https://www.xsocialmedia.com/legal-industry/ (Buy leads from experienced vendors) https://leadersinmasstorts.com/services/co-counsel/ (Consider co-counseling with some of the best) https://mtmp.com/hotel-accommodations/ (Stay informed by being amongst the first to know) Send us your questions at ask@incamerapodcast.com Enjoy the show? Please don't forget to subscribe, tell your coworkers, and leave us a review!
Attorney Brent Wisner discusses legal actions against the corporation that made heartburn medication Zantac. The trial-ready team of attorneys at Baum Hedlund Aristei & Goldman intend to hold the makers of Zantac accountable for allegedly concealing the ranitidine cancer link. With more than $4 billion in verdicts and settlements won across all practice areas, we have the experience and track record needed to secure maximum compensation for our clients. For more info: https://www.baumhedlundlaw.com/prescription-drugs/zantac-cancer-lawsuit/ --- Send in a voice message: https://anchor.fm/rfkjr/message
© 2020-2025 Ivy Podcast Discovery LLC
